• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Milestone Scientific Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    4/22/25 4:10:54 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    mlss20250422_8k.htm
    false 0000855683 0000855683 2025-04-22 2025-04-22
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): April 22, 2025
     
    Milestone Scientific Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction
    of incorporation)
     
    001-14053
    (Commission
    File Number)
     
    13-3545623
    (IRS Employer
    Identification No.)
     
         
    425 Eagle Rock Avenue
    Suite 403
    Roseland, New Jersey
    (Address of principal executive offices)
     
    07068
    (Zip Code)
     
    Registrant’s telephone number, including area code (973) 535-2717
     
    (Former name or former address, if changed since last report.)
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name on exchange on which registered
    Common Stock
    MLSS
    NYSE American
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
     
     

     
     
    Item 4.01 Changes in Registrant’s Certifying Accountant
     
    Based on information provided by Marcum LLP ("Marcum"), the independent registered public accounting firm of Milestone Scientific Inc. (the "Company"), CBIZ CPAs P.C. ("CBIZ CPAs") acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company's independent registered public accounting firm through April 22, 2025. On April 22, 2025, Marcum resigned as the Company's independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately. The engagement of CBIZ CPAs was approved by the Audit Committee of the Company's Board of Directors. The services previously provided by Marcum will now be provided by CBIZ CPAs.
     
    Marcum's reports on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
     
    During the Company's two most recent fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through April 22, 2025, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with its reports on the Company's consolidated financial statements for such years. In addition, during the Company's two most recent fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through April 22, 2025, there were no "reportable events," as defined in Item 304(a)(1)(v) of Regulation S-K.
     
    During the fiscal years ended December 31, 2024 and 2023 and through April 22, 2025, neither the Company nor anyone on its behalf consulted with CBIZ CPAs regarding (i) the application of accounting principles to any specified transaction, either completed or proposed or the type of audit opinion that might be rendered on the Company's consolidated financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a "disagreement," as defined in Item 304(a)(1)(iv) of Regulation S-K, or a "reportable event," as defined in Item 304(a)(1)(v) of Regulation S-K.
     
    The Company provided Marcum with a copy of the above disclosures and requested that Marcum furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made above. A copy of Marcum's letter dated April 22, 2025 is attached as Exhibit 16.1 to this Current Report on Form 8-K.
     
    Item 9.01 Financial Statements and Exhibits
     
    (d) Exhibits. The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
     
    16.1
    Letter from Marcum LLP, dated April 22, 2025, addressed to the Securities and Exchange Commission.
     
    104
    Cover Page Interactive Data file (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
             
     
    MILESTONE SCIENTIFIC INC.
     
     
    Dated: April 22, 2025 
    By:  
    /s/ Neal Goldman
     
       
    Neal Goldman, 
     
       
    Interim Chief Executive Officer
     
     
     
     
     
    Get the next $MLSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

      ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde

      5/19/25 10:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025

      ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, "We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both the clinical

      5/15/25 4:15:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025

      Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "While 2024 was a year of transition for Milestone Scientific, we laid the foundation for a strong rebound in 2025. We foc

      4/15/25 4:10:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

      ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde

      5/19/25 10:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

      ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti

      11/14/24 4:00:00 PM ET
      $CTHR
      $MLSS
      Consumer Specialties
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Milestone Scientific Appoints Pain Management Industry Veteran Dr. Didier Demesmin to its Board of Directors

      ROSELAND, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors. Dr. Demesmin is an interventional pain medicine physician who is double board-certified in both anesthesiology and pain medicine. He is the founder of University Pain and Spine center, a well-respected interventional pain management and spine surgery clinic that operates 7 offices across New Jersey and New York. He is also the founder of STEMMEE Surgery Center, an ambulatory surgery center providing st

      9/12/23 11:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    SEC Filings

    See more
    • Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      5/19/25 2:05:20 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Milestone Scientific Inc.

      10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      5/15/25 4:01:13 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      4/22/25 4:10:54 PM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bp4 S.R.L. sold $12,963 worth of shares (14,000 units at $0.93), decreasing direct ownership by 0.15% to 9,618,457 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      6/6/25 2:14:12 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Large owner Bp4 S.R.L. sold $20,744 worth of shares (22,118 units at $0.94), decreasing direct ownership by 0.23% to 9,632,457 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      6/3/25 4:00:42 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Large owner Bp4 S.R.L. sold $16,912 worth of shares (17,617 units at $0.96), decreasing direct ownership by 0.18% to 9,654,831 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      5/30/25 5:08:10 PM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Financials

    Live finance-specific insights

    See more
    • Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

      Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t

      11/14/24 4:30:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call

      ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 15th, 2024, to discuss the company's financial results for the third quarter ended September 30, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 169295. A webcast and replay of the call may be acc

      11/12/24 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024

      Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, "We are successfully advancing our reimbursement strategy for the CompuFlo®

      8/15/24 7:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care